Response-guided HCV therapy combination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis C virus (HCV) treatments are lengthy, costly, and associated with significant side effects, necessitating the development of therapies that are shorter in duration and more patient-friendly.
Innovation Solution
A combination therapy using at least three active agents, including an RNA polymerase inhibitor, an NS5A inhibitor, and an NS3 serine protease inhibitor, administered in solid dosage forms such as tablets or capsules, with optional inclusion of additional inhibitors, to treat HCV infection in a response-guided manner, aiming for a sustained virologic response in 21 days or less.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard HCV treatments (peg-interferon-alpha with ribavirin, protease inhibitors, or Sovaldi) are used, then treatment efficacy is achieved, but treatment duration becomes lengthy (48 weeks to 12 weeks) and side effects increase
Solution Approach 1:
The patent combines multiple direct-acting antiviral agents (DAAs) targeting different HCV proteins (NS3 protease inhibitor, NS5A inhibitor, and NS5B polymerase inhibitor) into a single combination therapy regimen. This multi-component approach synergistically accelerates viral clearance while maintaining high efficacy, enabling treatment completion in 21 days or less without compromising reliability.
Solution Approach 2:
The invention changes the treatment duration parameter from the conventional 8-12 weeks to 21 days or less by optimizing the combination of antiviral agents. By adjusting the dosing regimen and selecting specific agent combinations (including at least one NS3 protease inhibitor, one NS5A inhibitor, and one NS5B polymerase inhibitor), the therapy achieves rapid virologic response within 21 days while maintaining sustained virologic response rates.
2Reliability
If current HCV treatments are used, then viral clearance is achieved, but treatment cost becomes prohibitive
Solution Approach 1:
The patent employs a 21-day or less treatment duration that reduces the total quantity of pharmaceutical substances required compared to conventional 8-12 week regimens. By shortening the treatment course while maintaining efficacy through optimized agent combinations, the overall treatment cost is reduced, making the therapy more economically viable for patients and healthcare systems.
3Reliability
If current HCV therapies are administered, then treatment efficacy is maintained, but patient compliance becomes difficult due to lengthy duration
Solution Approach 1:
The invention implements a dynamic, response-guided treatment approach where the duration and dosing of antiviral agents are optimized based on patient-specific viral kinetics and response patterns. This flexible regimen allows for personalized treatment length (minimum 21 days) that adapts to individual patient needs, improving compliance by reducing the burden of lengthy fixed-duration therapies while maintaining efficacy.
Data Source
AI summary
The present disclosure relates to solid dosage forms comprising anti-HCV compounds and methods of using such dosage forms to treat or prevent HCV infection. Direct-acting antiviral agents (DAAs) have a high cure rate, and favorable tolerability in persons infected with hepatitis C virus (HCV). However, shorter courses of therapy can improve adherence, affordability, and increase DAAs accessibility. The addition of an NS3 protease inhibitor to dual NS5A-NS5B (nucleoside) inhibitors enhances antiviral efficacy, and reduces treatment duration to 3 weeks (wks) in individuals with a rapid virologic response (RVR), defined as plasma HCV RNA<500, or <1,000, IU/mL by Day 2 of treatment.